Treatment of hypertension and diabetes mellitus in patients with chronic kidney disease: a review

• BAILIE GR, UHLIG K, LEVEY AS: Clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic kidney disease. Pharmacotherapy (2005) 20:491-502.
   Google Scholar
• NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. (2002) 39:1-266.
   PubMedGoogle Scholar
• ODDEN MC, WHOOLEY MA, SHLIPAK MG: Depression, stress, and quality of life in persons with chronic kidney disease: the heart and soul study. Nephron. Clin. Pract. (2006) 103(1):C1-C7.
   Google Scholar
• PERLMAN RL, FINKELSTEIN FO, LIU L et al.: Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am. J. Kidney Dis. (2005) 45(4):658-666.
   PubMed Web of Science ®Google Scholar
• GORODETSKAYA I, ZENIOS S, MCCULLOCH CE et al.: Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. (2005) 68(6):2801-2808.
   PubMed Web of Science ®Google Scholar
• BAILIE GR, EISELE G, LIU L et al.: Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. Nephrol. Dial. Transplant. (2005) 20(6):1110-1115.
   PubMed Web of Science ®Google Scholar
• ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 288(23):2981-2997.
   PubMed Web of Science ®Google Scholar
• NATIONAL KIDNEY FOUNDATION: NKF-K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney. Dis. (2004) 43(5):S1-S268.
   PubMed Web of Science ®Google Scholar
• CORESH J, WEI GL, MCQUILLAN et al.: Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988 – 1994). Arch. Intern. Med. (2001) 161(9):1207-1216.
   PubMed Web of Science ®Google Scholar
• CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure (The JNC 7 Report). JAMA (2003) 289(19):2560-2572.
   PubMed Web of Science ®Google Scholar
• MANLEY HJ: Role of angiotensin-converting-enzyme inhibition in patients with renal disease. Am. J. Health Syst. Phar. (2000) 57(Suppl. ):S12-S18.
   Google Scholar
• RUGGENENTI P, PERNA A, LORIGA G et al.: Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomized controlled trial. Lancet (2005) 365:939-946.
   PubMed Web of Science ®Google Scholar
• NORRIS K, BOURGOIGNE J, GASSMAN et al.: Cardiovascular outcomes in the African American study of kidney disease and hypertension (AASK) trial. Am. J. Kidney Dis. (2006) 48(5):739-751.
   PubMed Web of Science ®Google Scholar
• RYŠAVÁ R, TESARˇV, MERTA M: Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease. Clin. Pharmacol. (2005) 10(4):207-213.
   Google Scholar
• WEINBERGOVÁ O, METELKA R, VYMEˇTAL J et al.: Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency. Bio. Med. Paper (2004) 148(1):69-73.
   PubMedGoogle Scholar
• LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patient with nephropathy due to Type 2 diabetes. N. Engl. J. Med. (2001) 345(12):851-860.
   PubMed Web of Science ®Google Scholar
• STIGANT S, STEVENS S, LEVIN A: Nephrology 4: strategies for the care of adults with chronic kidney disease. CMAJ (2003) 168(12):1553-1560.
   PubMedGoogle Scholar
• SNYDER RW, BERNS JS: Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin. Dial. (2004) 17:365-370.
   PubMed Web of Science ®Google Scholar
• MIDDLETON RJ, FOLEY RN, HEGARTY J et al.: The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol. Dials. Transplant. (2006) 21:88-92.
   PubMed Web of Science ®Google Scholar
• The sixth report of the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC-VI). Arch. Intern. Med. (1997) 157:2413-2246.
   PubMedGoogle Scholar
• HEYKA RJ: Lifestyle management and prevention of hypertension. Lifestyle Med. (1999):109-119.
   Google Scholar
• US DEPARTMENT OF HEALTH AND HUMAN SERVICES: Physical activity and health: a report of the surgeon general. Atlanta GA: Department of health and human services, centers for disease control and prevention, National center for chronic disease prevention and health promotion (1996).
   Google Scholar
• CHARPENTIER G, RIVELINE JP, VARROUD-VIAL M: Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab. (2000) 26(Suppl. 4):73-85.
   PubMed Web of Science ®Google Scholar
• ARONOFF GR, BERNS JS, BRIER ME et al.: Drug prescribing in renal failure. Dosing Guidelines for Adults. 4th Edition, American College of Physicians, Philadelphia (1999).
   Google Scholar
• CAMPOY S, ELWELL R: Pharmacology & CKD. Am. J. Nursing (2005) 105(9):60-71.
   PubMedGoogle Scholar
• WELLS BG, DIPIRO JT, SCHWINGHAMMER TL, HAMILTON CW: Diabetes mellitus. In: Pharmacotherapy Handbook. 6th Edition, Brown M, Naglieri (Eds), McGraw-Hill Medical Publishing Division, US (2006):186-188.
   Google Scholar
• LALAU JD, WESTEEL PF, DEBUSSCHE X et al.: Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin. Int. Care Med. (1987) 13:383-387.
   PubMed Web of Science ®Google Scholar
• LALAU JD, ANDREJAK M, MORINIERE P et al.: Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int. J. Clin. Pharmacol. Ther. Toxicol. (1989) 27:285-288.
   PubMedGoogle Scholar
• HOLSTEIN A, PLASCHKE A, HAMMER C et al.: Characteristics and time course of severe glimepiride-versus glibenclamide-induced hypoglycaemia. Eur. J. Clin. Pharmacol. (2003) 59:91-97.
   PubMed Web of Science ®Google Scholar
• HOLSTEIN A, EGBERTS EH: Risk of hypo glycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes (2003) 111:405-414.
   PubMed Web of Science ®Google Scholar
• NESTO RW, BELL D, BONOW RO et al.: Thiazolidinediones use, fluid retention, and congestive heart failure: a consenus statement from the American heart association and American diabetes association. Circulation (2003) 108:2941-2948.
   PubMed Web of Science ®Google Scholar
• HOLLENBERG NK: Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am. J. Med. (2003) 115(Suppl. 8A):S111-S115.
   Web of Science ®Google Scholar
• NISSEN S, WOLSKI K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. (2007) 356(24):2457-2471.
   PubMed Web of Science ®Google Scholar
• NISSENSON AR, COLLINS AJ, HURLEY J et al.: Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J. Am. Soc. Nephrol. (2001) 12:1713-1720.
   PubMed Web of Science ®Google Scholar
• KHAN SS, KAZMI WH, ABICHANDANI R et al.: Health care utilization among patients with chronic kidney disease. Kidney Int. (2002) 62:229-236.
   PubMed Web of Science ®Google Scholar
• SHODA J, KANNO Y, SUZUKI H: A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors an angiotensin receptor blockers in patients with non-diabetic nephropathy. Jpn. Soc. Int. Med. (2006) 45:193-198.
   Google Scholar
• IMAI E: Is ACEI superior to ARB in CKD? Jpn. Soc. Int. Med. (2006) 45:179-183.
   Google Scholar
• DIPIRO JT, TALBERT RL, YEE GC et al.: Chronic kidney disease: progression-modifying therapies. In: Pharmacotherapy: A Pathophysiologic Approach. Brown M, Hall A, Edmonson, Boyle PJ (Eds), McGraw-Hill Medical Publishing Division, USA (2005):804.
   Google Scholar
• 2006 Drug Topics Red Book. Montvale, MJ: Thomson PDR (2006).
   Google Scholar

Websites

• http://www.usrds.org/atlas.htm United States Renal Data System: Atlas (2006).
   Google Scholar
• http://care.diabetesjournals.org/cgi/reprint/29/suppl_1/s4 American Diabetes Association. Standards of Medical Care in Diabetes – 2006 (2006).
   Google Scholar
• http://care.diabetesjournals.org/cgi/reprint/30/suppl_1/S4 American Diabetes Association. Standard of Medical Care in Diabetes – 2007 (2007).
   Google Scholar
• https://connect.inova.com/mdxcgi/mdxhtml.exe?&tmpl=mdxhome.tm1&SCRNAME=mdxhome&CTL=/home2/mdx/mdxcgi/megat.sys MICROMEDEX (2006).
   Google Scholar
• http://www2.cdc.gov/drugs/ CDC HealthCare Statistic: Ambulatory Care Drug Database System (2006).
   Google Scholar